At a glance

ClinicalIndex Comparison Record

Phase 4Completed

Drug / intervention

Aranesp®drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117039

NCT00117039Phase 4Completed

Compare CT.gov

SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp® at 300 Mcg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy

Amgen·interventional·Posted Jul 4, 2005·Updated Oct 15, 2008

In Brief

A Phase 4 clinical trial evaluating Aranesp® for Anemia and Neoplasms. Completed.

Detailed Summary

The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network (NCCN) guidelines).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAnemia, Neoplasms

Countries--

Collaborators--

Timeline

Phase 4CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2004

Study CompletionApr 2005

First PostedJul 2005

TodayJul 2026

First PostedJul 4, 2005

Enrollment StartJan 1, 2004

Study CompletionApr 1, 2005

TodayJul 2, 2026

Posted 21.0 years ago

Interventions

Aranesp®drug